ICWA

RSV Respiratory syncytial virus

RSV: The Disease and Pipeline Vaccines

Despite effectiveness and safety issues, a vaccine targeting Respiratory Syncytial Virus (RSV) by GlaxoSmithKline Biologicals (GSK) was approved by the FDA on May 3, 2023 for people ages 60 and older, and now Pfizer’s RSV vaccine targeting pregnant women is moving through the perfunctory steps of captured federal agencies on it’s way to licensing. Listen to …

RSV: The Disease and Pipeline Vaccines Read More »

Powerful Public Comment to National Academies re: Adverse Vaccine Events

On March 30, 2023 the National Academies of of Sciences, Engineering, and Medicine heard an hour and a half of powerful public comment about vaccine adverse events. The closed-door meeting was minimally described as: “This is a virtual committee meeting. Committee members will meet in closed deliberative sessions to discuss the report. There will be …

Powerful Public Comment to National Academies re: Adverse Vaccine Events Read More »